Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.55 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.55 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.53 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676699 | 0.96 | OPRM1 (0.57) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL31676697 | 0.93 | OPRM1 (0.59) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL30233902 | 0.92 | OPRM1 (0.62) | OPRM1OPRD1NPFFR1NPFFR2NMUR2 | |
| SCHEMBL32664435 | 0.91 | NTSR2 (0.58) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL30402818 | 0.90 | NMUR2 (0.66) | OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL29531543 | 0.90 | OPRD1 (0.55) | OPRM1OPRD1NPFFR1NPFFR2 | |
| SCHEMBL31187483 | 0.88 | NMUR2 (0.63) | OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL31316687 | 0.88 | OPRM1 (0.63) | OPRM1OPRD1 | |
| SCHEMBL31410880 | 0.88 | OPRM1 (0.58) | OPRM1OPRD1NPFFR1NPFFR2NMUR2 | |
| SCHEMBL30695568 | 0.88 | OPRM1 (0.56) | OPRM1OPRD1NPFFR1NPFFR2NMUR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088119-B | Peptides having anticancer activity, and pharmaceutical composition, health functional food composition and functional cosmetic composition containing the same as active ingredient | 汉阳大学校产学协力团 | 2023-08-18 | — | — | CN | claimed |
| US-12605453-B2 | CP2C-targeting peptide-based anticancer agent | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2026-04-21 | — | — | US | disclosed |
| CN-110088119-B | Peptides having anticancer activity, and pharmaceutical composition, health functional food composition and functional cosmetic composition containing the same as active ingredient | 汉阳大学校产学协力团 | 2023-08-18 | — | — | CN | disclosed |
| CN-110088119-B | Peptides having anticancer activity, and pharmaceutical composition, health functional food composition and functional cosmetic composition containing the same as active ingredient | 汉阳大学校产学协力团 | 2023-08-18 | — | — | CN | disclosed |
| US-20230078718-A1 | UNSATURATED FATTY ACID-CONJUGATED CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-4101470-A1 | UNSATURATED FATTY ACID-CONJUGATED CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | Industry-University Cooperation Foundation Hanyang University (KR) | 2022-12-14 | — | — | EP | disclosed |
| CN-115361975-A | Anticancer agent based on unsaturated fatty acid conjugated CP2C targeting peptide | 汉阳大学校产学协力团 | 2022-11-18 | — | — | CN | disclosed |
| EP-4005583-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | Industry - University Cooperation Foundation Hanyang University (KR) | 2022-06-01 | — | — | EP | disclosed |
| US-20220160888-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160888-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | SREBF2, BCLAF1, CIP2A | OPRM1 4060/4885OPRD1 4157/4885NPFFR1 1114/4885 |
| US-20230078718-A1 | UNSATURATED FATTY ACID-CONJUGATED CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | ZDHHC2, FFAR2, SLC27A2 | OPRM1 4383/4885OPRD1 4413/4885NPFFR1 345/4885 |
| US-12605453-B2 | CP2C-targeting peptide-based anticancer agent | SREBF2, SLC27A2, ZDHHC2 | OPRM1 3263/4885OPRD1 3318/4885NPFFR1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.